Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time
Injection for Prostate Cancer: 7 Key Facts About ADT Hormone Therapy
Injection for Prostate Cancer: 7 Key Facts About ADT Hormone Therapy 2

When you get a prostate cancer diagnosis, knowing about Androgen Deprivation Therapy (ADT) is key. At Liv Hospital, we offer top-notch care. We make sure you get the best advice and care for your ADT cancer therapy.

Prostate cancer is a big health issue. It’s the second most common cancer and a top cause of death in men. For those with advanced or spread-out cancer, ADT hormone therapy is a main treatment. Our team is here to help you, giving you all the care and advice you need.

Key Takeaways

  • Understanding ADT is key for patients with advanced or metastatic prostate cancer.
  • Liv Hospital offers trusted care protocols for ADT therapy.
  • ADT lowers male hormone levels to slow cancer cell growth.
  • Expert guidance is available for ADT patients.
  • We focus on you, the patient, in every step of ADT therapy.

Understanding Prostate Cancer and Hormone Dependency

androgen deprivation therapy prostate cancer
Injection for Prostate Cancer: 7 Key Facts About ADT Hormone Therapy 3

Prostate cancer’s link with hormones is complex. Knowing this is key for good treatment. Prostate cancer cells often need hormones, like androgens, to grow and live.

The Role of Androgens in Prostate Cancer Growth

Androgens, like testosterone, are important in prostate cancer growth. These hormones help prostate cancer cells grow. Androgen deprivation therapy (ADT) tries to lower androgen levels to slow cancer growth.

How Hormone Dependency Affects Treatment Decisions

The extent to which prostate cancer depends on hormones affects treatment choices. For hormone-dependent cancer, treatments that lower hormone levels or block their action are used. We look at many factors, like cancer stage and patient health, to choose the best treatment.

When ADT Becomes Necessary in Cancer Progression

ADT is needed when prostate cancer gets advanced or spreads. At this stage, lowering androgen levels can slow disease growth and ease symptoms.

Factors Influencing ADT NecessityDescription
Cancer StageAdvanced or metastatic prostate cancer often requires ADT to slow disease progression.
PSA LevelsRising PSA levels may indicate the need for ADT to control cancer growth.
Patient HealthOverall health and presence of comorbidities influence ADT decisions.

What is Androgen Deprivation Therapy (ADT)?

adt therapy meaning
Injection for Prostate Cancer: 7 Key Facts About ADT Hormone Therapy 4

Androgen Deprivation Therapy (ADT) is a key treatment for advanced prostate cancer. It aims to lower hormone levels that help cancer grow. ADT is also called hormone therapy and is vital for managing prostate cancer, mainly in its advanced stages.

The Science Behind ADT Therapy Meaning

ADT works by reducing androgens like testosterone and DHT in the body. These hormones help prostate cancer cells grow. By lowering these hormone levels, ADT slows down or stops cancer cell growth. This is done through medications that either stop androgen production or block their action on cancer cells.

Historical Development of Hormone Treatments

Hormone therapy for prostate cancer has a long history, starting in the early 20th century. At first, surgical castration was used to lower androgen levels. Later, medical therapies were developed as alternatives to surgery. The introduction of LHRH agonists and antagonists was a big step forward, providing more effective and reversible treatments.

Goals of ADT in Advanced and Metastatic Disease

The main goal of ADT in advanced and metastatic prostate cancer is to control the disease. It does this by reducing androgen levels, which slows cancer growth. ADT can also help ease symptoms, improve quality of life, and potentially extend survival. It is often used with other treatments like radiation or chemotherapy.

Goals of ADTDescriptionBenefits
Control Disease ProgressionReduce androgen levels to slow cancer growthSlows down cancer progression
Alleviate SymptomsReduce symptoms associated with advanced prostate cancerImproves quality of life
Extend SurvivalPotentially extend the life of patients with metastatic diseaseEnhances survival rates

Injection for Prostate Cancer: How ADT Hormone Shots Work

ADT hormone shots are key in treating prostate cancer. They aim to lower testosterone, which helps cancer grow. This is because testosterone feeds the growth of prostate cancer cells.

The Mechanism of Action in Testosterone Suppression

ADT hormone shots work by lowering testosterone levels. They use LHRH (Luteinizing Hormone-Releasing Hormone) analogs. These first increase testosterone but then lower it, stopping cancer growth.

Delivery Methods and Administration Techniques

These shots are given as injections into the muscle. How often depends on the drug, from monthly to every six months. Doctors pick the best schedule based on the patient and cancer type.

Immediate vs. Delayed Effects of Hormone Injections

The shots’ effects happen right away and later. First, testosterone might go up, then drop. This drop in testosterone is key to slowing cancer.

Patients may see tumor and PSA levels go down. They might also face side effects. Knowing how these shots work helps patients understand their treatment better.

Types of Prostate Cancer Hormone Therapy Drugs

Hormone therapy is a key part of treating prostate cancer. It uses drugs to lower androgen levels. Androgen deprivation therapy (ADT) is a main treatment for advanced prostate cancer. We will look at the different hormone therapy drugs used in prostate cancer treatment.

LHRH Agonist Examples

LHRH agonists first increase hormone production, then lower testosterone levels. Examples include:

  • Leuprolide (Lupron, Eligard): A common LHRH agonist given by injection.
  • Goserelin (Zoladex): An LHRH agonist implanted under the skin.
  • Triptorelin (Trelstar): Used for advanced prostate cancer.

LHRH Antagonists

LHRH antagonists block LHRH, quickly lowering testosterone levels. Examples include:

  • Degarelix (Firmagon): An LHRH antagonist given by injection.
  • Relugolix (Orgovyx): An oral LHRH antagonist, an alternative to injections.

Antiandrogens as Androgen Deprivation Therapy Examples

Antiandrogens block androgens at the cellular level. Examples include:

  • Bicalutamide (Casodex): A non-steroidal antiandrogen used with other treatments.
  • Enzalutamide (Xtandi): A newer antiandrogen for castration-resistant prostate cancer.

Knowing about the different hormone therapy drugs for prostate cancer is important. It helps in making informed treatment choices. We suggest talking to a healthcare provider to find the best treatment.

Prostate Cancer Injections Every 6 Months: Treatment Schedules

Knowing the treatment schedule for prostate cancer injections is key to managing the disease well. Androgen Deprivation Therapy (ADT) is a common treatment for advanced prostate cancer. The frequency of injections greatly affects patient outcomes.

Continuous vs. Intermittent Therapy Protocols

ADT can be given through continuous or intermittent therapy. Continuous therapy means ongoing hormone injections, usually every 1 to 6 months. Intermittent therapy involves treatment cycles followed by breaks. Studies show intermittent ADT can reduce side effects while keeping cancer under control.

Long-Acting Formulations and Their Benefits

Long-acting ADT injections, given every 3 to 6 months, are gaining popularity. They are convenient and help patients stick to their treatment. These injections lead to consistent hormone suppression, which can improve cancer control.

Monitoring Treatment Effectiveness Through PSA Testing

It’s important to check if ADT is working, and PSA testing is key. Regular PSA tests help doctors see if the treatment is effective. They can then adjust the treatment plan as needed. For more on hormone therapy for prostate cancer, visit Mayo Clinic’s resource on hormone therapy.

Treatment ProtocolFrequencyBenefits
Continuous ADTOngoing injections every 1-6 monthsConsistent hormone suppression
Intermittent ADTCycles of treatment with periods offReduced side effects, maintained effectiveness
Long-acting ADTInjections every 3-6 monthsImproved patient compliance, consistent hormone suppression

Benefits of ADT Treatment for Prostate Cancer

ADT treatment for prostate cancer has many benefits. It improves patient outcomes in several ways. It is key in managing advanced prostate cancer, boosting quality of life and survival rates.

Tumor Shrinkage and PSA Response Rates

ADT helps shrink tumors and lower Prostate-Specific Antigen (PSA) levels. Studies show it can significantly reduce PSA levels. This means the disease is being controlled well.

“ADT has been a game-changer in managing prostate cancer, allowing us to control the disease more effectively.”

Leading Oncologist

Extending Survival in Metastatic Disease

ADT also extends life for those with metastatic prostate cancer. It slows disease progression by reducing androgen production. This gives patients more time and a better prognosis.

Combination with Radiation and Chemotherapy

ADT works well with other treatments like radiation and chemotherapy. This combination makes treatment more effective, leading to better results for patients.

Quality of Life Improvements for Symptomatic Patients

ADT greatly improves life for those with symptoms. It reduces androgens, easing pain and urinary issues. This makes managing the condition easier for patients.

In summary, ADT treatment for prostate cancer brings many benefits. It includes tumor shrinkage, better PSA response, longer survival, and improved quality of life. As we keep improving prostate cancer treatment, ADT’s role will remain vital.

Side Effects and Management of Hormone Therapy for Prostate Cancer

ADT for prostate cancer has both good and bad sides. It helps control the disease but also causes side effects. It’s important to know about these effects to give patients the best care.

Short-Term Side Effects

When starting ADT, patients often face immediate side effects. These can affect their daily life.

Hot Flashes and Sexual Dysfunction

Hot flashes are common and can be uncomfortable. Sexual problems also occur, affecting relationships and well-being.

Mood Changes and Fatigue

Mood swings and tiredness are common. Some patients may feel depressed or anxious. These changes can be hard for patients and their families.

Long-Term Health Concerns

Long-term use of ADT can lead to serious health issues. These need careful watching.

Bone Density Loss and Fracture Risk

Bone density loss is a big risk. It can lead to osteoporosis and fractures, which are more serious for older patients.

Metabolic Changes and Cardiovascular Risks

ADT can also cause metabolic changes. This can increase the risk of heart disease. It’s important to watch blood pressure and lipid levels.

Strategies to Minimize ADT Complications

Healthcare providers use several ways to reduce ADT side effects. These include:

  • Regular checks on bone density and heart health
  • Changes in diet and exercise
  • Medicines like bisphosphonates for bone health

By understanding ADT side effects and using these strategies, patients can make better choices. This can improve their quality of life.

ADT and Prostate Cancer Resistance: Challenges and Solutions

Understanding ADT resistance is key to better prostate cancer treatment. As we use Androgen Deprivation Therapy (ADT) for prostate cancer, resistance is a big challenge.

Understanding Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Cancer (CRPC) happens when cancer grows despite ADT. It shows in rising PSA levels and more aggressive disease.

Mechanisms of Resistance Development

ADT resistance comes from genetic changes in the androgen receptor. These changes let cancer cells grow even with low testosterone.

Next-Generation Hormone Therapies for Resistant Disease

New treatments are being made to fight ADT resistance. These include next-generation anti-androgens and treatments targeting the androgen receptor pathway.

Combining Therapies to Overcome Resistance

Using different treatments together can beat resistance. This might mean combining ADT with chemotherapy or targeted treatments for better CRPC outcomes.

By tackling ADT resistance and trying new treatments, we can better manage prostate cancer. This will help improve patient results.

The Future of Endocrine Therapy for Prostate Cancer

Looking ahead, endocrine therapy for prostate cancer is set to see big changes. New discoveries are on the way to make treatments better for patients.

Emerging Treatment Approaches and Clinical Trials

New treatments are being tested in clinical trials. They include new androgen receptor inhibitors and better ways to deliver treatments. Also, combining endocrine therapy with other treatments is being explored.

Personalized Medicine in Hormone Therapy Selection

Personalized medicine is key in choosing hormone therapy for prostate cancer. By looking at each patient’s unique traits and tumor, we can make treatments more effective and reduce side effects.

Biomarkers for Treatment Response Prediction

Finding reliable biomarkers is vital for predicting how well treatments will work. Research is underway to find biomarkers that show which treatments will work best for each patient. This will lead to more precise and effective care.

Conclusion: Making Informed Decisions About ADT Hormone Shots for Prostate Cancer

Understanding Androgen Deprivation Therapy (ADT) is key when dealing with prostate cancer. ADT hormone shots are a big part of treating advanced prostate cancer. They help manage the disease effectively.

Patients with prostate cancer have many choices to make about their treatment. Knowing the good and bad of ADT helps them make choices that fit their health goals and what they prefer.

Good prostate cancer treatment does more than just fight the disease. It also supports the patient’s overall health. As we learn more about ADT, we can give better care that meets all our patients’ needs.

Our main aim is to help patients make choices that are best for them. By understanding ADT and its role in treating prostate cancer, we can work together to get the best results.

What is Androgen Deprivation Therapy (ADT) and how does it work in treating prostate cancer?

ADT is a treatment that lowers male hormones to slow prostate cancer growth. It reduces testosterone, a hormone that helps cancer cells grow.

What are the different types of hormone therapy drugs used in prostate cancer treatment?

Hormone therapy drugs for prostate cancer include LHRH agonists, LHRH antagonists, and antiandrogens. LHRH agonists like leuprolide and goserelin are examples. Antiandrogens, such as bicalutamide, block androgens’ action on cancer cells.

How are ADT hormone shots administered, and what are the different delivery methods?

ADT shots are given by injection, either in the muscle or under the skin. The shots are given at different times, from every 1-6 months. Some shots last 6 months, making treatment easier for patients.

What are the benefits of ADT in prostate cancer treatment?

ADT helps shrink tumors and improve PSA levels. It also extends life in advanced disease and boosts quality of life. It can be used with other treatments to better outcomes.

What are the common side effects of hormone therapy for prostate cancer, and how can they be managed?

Side effects include hot flashes, fatigue, weight gain, and low libido. Long-term risks include osteoporosis and heart disease. Regular exercise, a healthy diet, and monitoring can help manage these issues.

What is castration-resistant prostate cancer, and how is it treated?

Castration-resistant prostate cancer grows despite ADT. Treatments include new hormone therapies, chemotherapy, and other emerging options.

How is treatment effectiveness monitored during ADT, and what role does PSA testing play?

PSA testing is key to monitoring ADT success. Changes in PSA levels show if treatment is working or if cancer is progressing.

What are the future directions in endocrine therapy for prostate cancer?

Future treatments include personalized medicine and biomarkers for predicting treatment response. Ongoing trials aim to improve outcomes with new therapies and combinations.

Can ADT be used intermittently, and what are the benefits of intermittent therapy?

Yes, ADT can be used in cycles with breaks. This approach reduces side effects and improves life quality. It may also delay cancer resistance.

References

  • National Cancer Institute (NCI): https://www.cancer.gov/types/prostate/prostate-hormone-therapy-fact-sheet
  • American Cancer Society (ACS): https://www.cancer.org/cancer/types/prostate-cancer/treating/hormone-therapy.html
  • National Center for Biotechnology Information (NCBI) / PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC8702790/

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Get a Free Quote

Response within 2 hours during business hours

Clinics/branches
GDPR

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
Trusted Worldwide
30
Years of
Experience
30 Years Badge
Health Türkiye Accreditation

Trusted Worldwide

30 Years of Experience

Patient Reviews
Reviews from 9,651
4,9
Was this content helpful?
Your feedback helps us improve.
What did you like?
Share more details about your experience.
You must give consent to continue.

Thank you!

Your feedback has been submitted successfully. Your input is valuable in helping us improve.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Prof. MD. Yasemin Altuner Torun

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 510 67 91